Skip to content
GLP-1 Scorecard
Menu

Evidence review

How to Choose a GLP-1 Provider: A Six-Point Checklist

A data-first checklist for picking a GLP-1 telehealth provider — price, dosing, oversight, monitoring, fulfillment, and contract terms.

By The Scorecard Lab, Provider Testing Desk

The medication is not the hard part anymore. The provider is. Two people can take the exact same molecule and have wildly different experiences depending on who prescribes it, what they pay, and what happens when a side effect shows up. This checklist scores the provider — not the drug — using the same six dimensions we grade every company on.

The molecule works; the provider is the variable The trial record on GLP-1 weight management is strong and specific. Once-weekly semaglutide 2.4 mg produced a mean body-weight change of about −14.9% over 68 weeks in the STEP-1 trial[[cite:1]], and tirzepatide reached up to roughly −20.9% at 72 weeks in SURMOUNT-1[[cite:2]]. Those numbers come from tightly run studies with real clinical supervision. A telehealth provider is the layer between that evidence and your kitchen counter — and that layer is where quality actually varies. Grade it deliberately.

The six dimensions we score Our [WeighScore methodology](/methodology) runs every provider through the same rubric, weighted like this:

Cost value (25%), dose and formulation (20%), clinical oversight (20%), labs and monitoring (15%), fulfillment (12%), and contract terms (8%). Use the same six as your personal checklist. Here is what each one really means when you are the one paying.

1. Normalize the price before you compare it The headline number is almost never the number you pay in month four. Introductory pricing, dose-based step-ups, and "membership plus medication" splits make two providers that look identical on the landing page diverge by hundreds of dollars once you titrate up. Convert every offer to a single figure: total dollars per month at your expected maintenance dose, after any intro period ends. Our breakdown of [what compounded GLP-1 costs per month](/what-compounded-glp1-costs-per-month) shows how to do that conversion.

2. Check what molecules and doses are on the menu A provider that only stocks one molecule at two doses cannot follow you if your body needs to switch or titrate differently. Look for both semaglutide and tirzepatide, a full titration ladder, and clarity on formulation (injectable vs. oral or sublingual). If you are still deciding which drug to ask about, start with [semaglutide vs. tirzepatide](/semaglutide-vs-tirzepatide).

3. Confirm there is real clinical oversight You want a licensed prescriber who reviews your history, not a rubber-stamp intake form. Ask: Who signs the prescription? Can you reach a clinician between visits? What is the escalation path if you have a serious side effect? A provider that cannot answer those in plain language loses points on the dimension that matters most for safety.

4. Ask whether labs and monitoring are included Baseline labs, periodic check-ins, and structured side-effect monitoring are either built into the program or bolted on at extra cost — and the difference changes both your safety and your true price. A program that "includes monitoring" but never actually checks in is scoring on paper only. Pin down the cadence.

5. Interrogate fulfillment and sourcing Where does the drug come from, and can they tell you? Brand-name products are FDA-approved and dispensed from the manufacturer's supply chain; compounded products come from 503A pharmacies or 503B outsourcing facilities under a different framework. Understand which you are getting before you buy — see [compounded vs. brand-name GLP-1](/compounded-vs-brand-name-glp1) and, if you are considering compounded, [is compounded semaglutide legit and safe?](/is-compounded-semaglutide-legit-and-safe)

6. Read the contract before the first charge Cancellation friction, refund posture, auto-renewal honesty, and lock-in are where good-looking offers quietly go bad. Find the cancel button before you subscribe. If you cannot locate the terms, or they require a phone call to escape, treat that as a scored weakness — not a formality.

The 60-second scorecard Before you enter a card number, you should be able to answer, in one sentence each: what you pay per month at maintenance; which molecules and doses are available; who your prescriber is and how to reach them; whether labs and monitoring are included; where the medication is sourced; and how you cancel. Six clean answers means a provider worth grading highly. Any blanks are the provider's problem to fix, not yours to excuse.

Where to start Rather than guess, compare graded providers side by side. Browse the full [provider reviews](/research) and head-to-head [comparisons](/compare), or start with our current top-graded partner, [CoreAge Rx](/reviews/coreage-rx). Every grade uses the same formula, and affiliate relationships never move the number — only which providers we spotlight.

Frequently asked questions

What is the single most important thing when choosing a GLP-1 provider?

Real clinical oversight. Price and convenience matter, but a licensed prescriber who reviews your history and is reachable when a side effect appears is what separates a medical program from a vending machine.

How do I compare prices fairly between GLP-1 providers?

Convert every offer to total dollars per month at your expected maintenance dose, after any introductory period ends. Intro pricing and dose-based step-ups make otherwise-identical offers diverge sharply once you titrate up.

Should I pick brand-name or compounded?

That depends on cost, availability, and your comfort with the compounding framework. Brand-name products are FDA-approved; compounded products are made by 503A or 503B pharmacies. Understand which you are getting before you subscribe.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.